Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Hosso Cooper

Internal Medicine Oak Lawn, IL Doctor of Osteopathy

NPI 1801820691 CMS profile 217332

4301 W 95Th Street, Oak Lawn, IL 60453

Open in the dashboard

General payments

$12,065

606 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Hosso Cooper of Oak Lawn, IL is reported in the CMS Open Payments database as having received $12,065 across 606 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,390 71
2024 General $1,584 83
2023 General $2,034 86
2022 General $1,878 87
2021 General $1,961 96
2020 General $1,166 68
2019 General $2,051 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Hosso Cooper
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jennifer Hosso Cooper were reported at $1,390. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jennifer Hosso Cooper Internal Medicine median Middle half National median
2019 $2,051 $159 $48–$570 $163
2020 $1,166 $119 $33–$402 $114
2021 $1,961 $135 $37–$521 $132
2022 $1,878 $141 $42–$496 $149
2023 $2,034 $149 $45–$519 $160
2024 $1,584 $154 $47–$537 $164
2025 $1,390 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,745 90 payments
  2. AbbVie, Inc. $1,207 59 payments
  3. Pfizer Inc. $1,116 68 payments
  4. AstraZeneca Pharmaceuticals LP $1,057 50 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $945 38 payments
  6. GlaxoSmithKline, LLC. $917 47 payments
  7. Lilly USA, LLC $801 42 payments
  8. Amgen Inc. $647 44 payments
  9. Janssen Pharmaceuticals, Inc $426 21 payments
  10. Otsuka America Pharmaceutical, Inc. $371 16 payments
  11. Other $2,833 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,945 603 payments
  2. Consulting Fee $100 1 payment
  3. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $833 46 payments
  2. UBRELVY $727 35 payments
  3. FARXIGA $714 30 payments
  4. RYBELSUS $656 34 payments
  5. JARDIANCE $492 20 payments
  6. Saxenda $436 21 payments
  7. Repatha $402 27 payments
  8. NURTEC ODT $401 25 payments
  9. TRELEGY ELLIPTA $400 22 payments
  10. XARELTO $399 19 payments
  11. Other $10,935 555 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

4,614

Median for Internal Medicine: 777

Drug cost

$153,640

Median for Internal Medicine: $73,373

Branded share of claims

9.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 15 $23,142
Eliquis Apixaban Brand 19 $21,813
Jardiance Empagliflozin Brand 12 $18,327
Januvia Sitagliptin Phosphate Brand 11 $14,668
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 55 $6,331
Atorvastatin Calcium Generic 558 $6,201
Levothyroxine Sodium Generic 313 $4,704
Losartan Potassium Generic 281 $3,829
Pantoprazole Sodium Generic 228 $3,530
Metoprolol Succinate Generic 153 $3,056

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$145,952

Of which drugs: $11,887

Medicare patients

221

Average age 74

Services billed

2,718

185 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Osteoporosis 74%
Arthritis 44%
Diabetes 29%
Ischemic heart disease 21%
Heart failure 18%
Depression 17%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 68 68 $5,400
Pcv20 vaccine im 90677 Office 14 14 $4,089

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $140
  • Lilly USA, LLC $27
$167 12 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $130
$130 — —
VRAYLAR
  • AbbVie, Inc. $123
$123 — —
NURTEC ODT
  • PFIZER INC. $118
$118 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

606 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record